Characteristics of study participants at randomization according to treatment arm
| . | Nadroparin and medical surveillance (N = 67) . | Medical surveillance alone (N = 68) . |
|---|---|---|
| Median age, y (range) | 34 (23-42) | 34 (19-45) |
| Body mass index, kg/m2, mean (SD) | 24 (4) | 24 (5) |
| White ethnicity, n (%) | 56 (84) | 54 (79) |
| Previous uncomplicated pregnancies, n (%) | 25 (37) | 23 (34) |
| Previous pregnancy complication, n (%)* | ||
| Preeclampsia | 16 (24) | 24 (35) |
| Mild | 0 | 0 |
| Severe | 11 (16) | 14 (21) |
| Unknown | 5 (8) | 10 (15) |
| Eclampsia | 0 | 0 |
| HELLP syndrome | 9 (13) | 3 (4) |
| Intrauterine fetal death | 25 (37) | 24 (35) |
| FGR | 16 (24) | 12 (18) |
| Placental abruption | 1 (2) | 4 (6) |
| Gestational week at randomization, mean (SD)‡ | 11 (2) | 11 (2) |
| Current smokers (≥ 5 cigarettes per day), n (%) | 5 (8) | 3 (5) |
| Screened for thrombophilia, n (%)† | 65 (97) | 66 (97) |
| Antithrombin deficiency | 2 (3) | 3 (5) |
| Protein C deficiency | 2 (3) | 0 |
| Protein S deficiency | 37 (57) | 39 (59) |
| Factor V Leiden | 3 (5) | 4 (6) |
| Prothrombin G20210A | 1 (2) | 1 (2) |
| Combined abnormalities | 1 (2)‡ | 0 |
| . | Nadroparin and medical surveillance (N = 67) . | Medical surveillance alone (N = 68) . |
|---|---|---|
| Median age, y (range) | 34 (23-42) | 34 (19-45) |
| Body mass index, kg/m2, mean (SD) | 24 (4) | 24 (5) |
| White ethnicity, n (%) | 56 (84) | 54 (79) |
| Previous uncomplicated pregnancies, n (%) | 25 (37) | 23 (34) |
| Previous pregnancy complication, n (%)* | ||
| Preeclampsia | 16 (24) | 24 (35) |
| Mild | 0 | 0 |
| Severe | 11 (16) | 14 (21) |
| Unknown | 5 (8) | 10 (15) |
| Eclampsia | 0 | 0 |
| HELLP syndrome | 9 (13) | 3 (4) |
| Intrauterine fetal death | 25 (37) | 24 (35) |
| FGR | 16 (24) | 12 (18) |
| Placental abruption | 1 (2) | 4 (6) |
| Gestational week at randomization, mean (SD)‡ | 11 (2) | 11 (2) |
| Current smokers (≥ 5 cigarettes per day), n (%) | 5 (8) | 3 (5) |
| Screened for thrombophilia, n (%)† | 65 (97) | 66 (97) |
| Antithrombin deficiency | 2 (3) | 3 (5) |
| Protein C deficiency | 2 (3) | 0 |
| Protein S deficiency | 37 (57) | 39 (59) |
| Factor V Leiden | 3 (5) | 4 (6) |
| Prothrombin G20210A | 1 (2) | 1 (2) |
| Combined abnormalities | 1 (2)‡ | 0 |